Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
Clinical trial NCT02535286 · COMPLETED
Trial details
- NCT number
- NCT02535286
- Sponsor
- TG Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-09-18
- Primary completion
- 2021-11-04
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.